Chimeric antigen receptor (CAR) T-cell (’Living Drug’) immunotherapy is showing promising results in the treatment of cancers. There are nine ongoing clinical trials (Phase I & II) at Memorial Sloan Kettering (MSK) and more on track to be initiated next year.
Over the years, MSK has accumulated a breadth of knowledge about developing and translating these clinical trials from bench to bedside – choosing the ideal antigen target, constructing clinical grade CARs and vectors, investigating in clinically relevant models, manufacturing, quality control, developing protocols for FDA approval, optimizing consent forms covering emerging ethical issues, managing complications, and conducting world-class correlative science.
In addition to the MSK faculty, national and international experts will discuss clinical and translational aspects of CARs, both for hematological malignancies and solid tumors.
The target audience is medical oncologists and oncology fellows in training, basic scientists and research fellows in training, immunologists, and surgeons with interest in tumor immunology and immunotherapy.
Memorial Sloan Kettering Cancer Center designates this conference for a maximum of 12.75 AMA PRA Category 1 Credits™. Each physician should claim only those hours of credit he/she actually spent in the conference.
Call for Abstracts
We are pleased to invite you to submit an Abstract for presentation at the CAR T-Cell CME Course. Abstracts for the poster session will be selected on the basis of their scientific merit and content quality. Selected abstracts will be awarded travel awards. All Abstracts must be submitted to Memorial Sloan Kettering Cancer Center by Friday, February 5, 2016. Please click here to submit an Abstract.